Key result
Aspirin use was associated with an increased risk of heart failure in a prior cohort study (HR 1.26; 95% CI 1.12-1.41), highlighting the need for randomized evidence from the ASPREE trial.
Why the study?
Does aspirin prevent incident heart failure in healthy older adults?
RCT
double-blinded
randomized
Does aspirin prevent incident heart failure in healthy older adults?
Observational data suggests aspirin may increase the risk of incident heart failure, prompting the need to examine randomized trial data such as the ASPREE trial.
Heart failure (HF) is now the leading cause of a first major cardiovascular event and the most common hospital discharge diagnosis in older adults. A recent cohort study by Mujaj et al included 30 000 individuals at risk for HF (mean age, 67 years), of whom 26% had a history of coronary artery disease. The analysis demonstrated an increased risk of HF in those taking aspirin (adjusted hazard ratio [HR], 1.26 [95% CI, 1.12–1.41]) but highlighted the need for evidence from randomized trials.2 ASPREE (Aspirin in Reducing Events in the Elderly (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01038583) was a double-blinded, randomized, placebo-controlled trial of aspirin in healthy older subjects.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2022) conducted an RCT in healthy older subjects. Aspirin vs. placebo was evaluated. Aspirin use was associated with an increased risk of heart failure in a prior cohort study (HR 1.26; 95% CI 1.12-1.41), highlighting the need for randomized evidence from the ASPREE trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: